# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: George H. W. Bush (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML018-SYN
- Date: 2026-05-08
- Fictional facility: St. Posthumous Health Center
- Fictional author: Douglas Whitford, MD
- Calendar frame: modern shifted

## What we are working on

- New irregular heartbeat that began as unusual tiredness on a run; wants to know whether he can keep running **S**
- Wants to get back to a full working schedule and to exercise as soon as it is safe **S**

## Your goals

- Resting heart rate below 110 per minute without palpitations while thyrotoxic. Target: 2026-05-20. Recorded outcome: Heart rate 72 in sinus rhythm on metoprolol two weeks after intake. **S**
- No atrial fibrillation once no longer thyrotoxic, confirmed by ambulatory monitoring before the anticoagulation decision. Target: 2026-09-11. Recorded outcome: Sinus rhythm throughout a 14-day ECG patch. **S**
- TSH within 0.4 to 4.0 mIU/L on levothyroxine. Target: 2026-10-16. Recorded outcome: TSH 6.4 on 75 mcg at the four-month review; 2.6 five weeks after the increase to 100 mcg. **S**
- Back to running three miles several days a week without symptoms. Target: 2026-09-11. Recorded outcome: Running three miles four days a week without palpitations. **S**

## What we agreed to do

- Rate control with metoprolol succinate 50 mg daily; no antiarrhythmic drug or cardioversion while thyrotoxic, because most thyrotoxic atrial fibrillation reverts once thyroid levels are normal; taper the beta-blocker once he is no longer thyrotoxic. Guideline: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026) **S**
- Stroke-risk and bleeding-risk scoring (CHA2DS2-VASc 1 for age 65 to 74; HAS-BLED 1 for age over 65) with a shared decision to continue apixaban 5 mg twice daily while thyrotoxic, then reassess once sustained sinus rhythm is confirmed after he is no longer thyrotoxic. Guideline: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026) **S**
- Methimazole 20 mg daily after a baseline blood count and liver tests, with written advice to stop it and call at once for fever, sore throat, mouth ulcers, jaundice, or dark urine; stop three days before radioactive iodine. Guideline: 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) **S**
- Endocrinology consultation to confirm Graves' disease, assess the eyes, and choose definitive treatment (radioactive iodine, long-term methimazole, or surgery). Guideline: 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) **S**
- After radioactive iodine: free T4 and total T3 within one to two months and then every four to six weeks until stable; levothyroxine once hypothyroid, started below full replacement; TSH four to eight weeks after each dose change, at six months once stable, then yearly; target TSH 0.4 to 4.0 mIU/L. Guideline: 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016); Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement (2014); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026) **S**
- Atrial fibrillation monitoring at every visit (heart rate and rhythm, blood pressure, weight, symptoms, activity, alcohol, tobacco), ECG when indicated, echocardiogram at diagnosis, CHA2DS2-VASc and HAS-BLED yearly, creatinine and blood count at baseline and yearly on apixaban, and sleep apnea screening at diagnosis and yearly. Guideline: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026) **S**
- Return to running in steps once the heart rate is controlled, aiming for about 210 minutes a week of moderate to vigorous activity; limit alcohol to no more than one drink a day. Guideline: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026) **S**

## Follow-up

- 2026-05-08: Post-hospital visit for new atrial fibrillation, with thyroid tests showing hyperthyroidism **S**
- 2026-05-20: Two-week review on methimazole, with endocrinology consultation **S**
- 2026-07-17: Seven-week review after radioactive iodine **S**
- 2026-09-11: Four-month review: levothyroxine titration and anticoagulation decision **S**
- 2026-10-16: Subsequent annual wellness visit **S**

This teaching document does not replace care from a qualified clinician.
